| Drug Discovery for Leishmaniasis Contributor(s): Rivas, Luis (Editor), Gil, Carmen (Editor) |
|
 |
ISBN: 1782628894 ISBN-13: 9781782628897 Publisher: Royal Society of Chemistry OUR PRICE: $198.55 Product Type: Hardcover Published: November 2017 |
| Additional Information |
| BISAC Categories: - Science | Chemistry - Clinical - Science | Life Sciences - Molecular Biology - Science | Life Sciences - Biochemistry |
| Series: Drug Discovery |
| Physical Information: 1.1" H x 6.4" W x 9.2" (1.70 lbs) 422 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: From a human health perspective, leishmaniasis is among the most important protozoan diseases, superseded only by malaria. Between 10 and 12 million people are affected by the disease and with no known vaccine, the development of new drugs is urgently required. This volume provides a perspective of current treatments and their challenges as well as discussing emerging strategies and methodologies that will drive new drug development for this 'neglected' disease. |
Contributor Bio(s): Rivas, Luis: - Dr Luis Rivas currently belongs to the scientific staff of the Center for Biological Research (Madrid, Spain) inside the Spanish National Council for Scientific Research Organization (Consejo Superior de Investigaciones Científicas, CSIC). He earned his PhD in Biochemistry (University Complutense of Madrid, 1984). After completing his PhD, he moved to the Weizmann Institute of Science, (Rehovot, Israel) and to Yale University (CT, USA) to complete his formation as a postdoctoral fellow. He focused on the design of antimicrobial peptides and on cell penetrating peptides as new drugs and vehicles for Leishmania chemotherapy. Another line is the elucidation of the mode of action of drugs targeting the bioenergetic mechanism of the parasite. He published 80 publications in referred international journals, mostly addressing Leishmania chemotherapy and molecular basis of peptide-pathogen interaction.Gil, Carmen: - Dr Carmen Gil is staff scientist at Center for Biological Research of Spanish National Council for Research (CSIC) with a background in Medicinal Chemistry and Pharmacy. She received her Ph.D. from Complutense University of Madrid in 2001. After a postdoctoral appointment at Bonn University (Germany) she joined the CSIC. Her research is oriented to the discovery and development of new small-molecules as innovative target-based drugs and her research areas have been focused on phosphodiesterase and kinase inhibitors as innovative drug candidates for neurodegenerative diseases. She is involved in different projects that apply her background and experience in the development of specific parasite phosphodiesterase and kinase inhibitors in the fight for neglected parasitic diseases. She is author of more than sixty scientific publications, has four active patents in the field and has contributed to several books. |